1999
DOI: 10.1111/j.1348-0421.1999.tb02468.x
|View full text |Cite
|
Sign up to set email alerts
|

Protective Immune Response to 16 kDa Immunoreactive Recombinant Protein Encoding the C‐Terminal VP1 Portion of Foot and Mouth Disease Virus Type Asia 1

Abstract: Recombinant protein of Foot and Mouth Disease Virus (FMDV) type Asia 1 corresponding to the C‐terminal half of VP1 was expressed in Escherichia coli. As an alternative to the synthetic peptide, this selected C‐terminal region was used as a protein vaccine in guinea pigs in order to study the immune response with various adjuvant formulations: immune stimulatory complexes (ISCOMs), Montanide ISA 206, Freund's incomplete adjuvant (FIA), lipopolysaccharide (LPS) and cytokine mixture. A primary dose of 40 μg/anima… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
5
0

Year Published

2004
2004
2018
2018

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(6 citation statements)
references
References 21 publications
1
5
0
Order By: Relevance
“…Vaccines adjuvanted with Montanide oils have been reported to retain potency for a longer period than conventional aqueous formulations and elicit early, heightened and protective antibody titres and long lasting immunity (Bayry et al., 1999). When administered intramuscularly, no evidence of toxicity, prolonged pyrexia or local reactions at the site of inoculations is reported (Barnett et al., 1996).…”
Section: Discussionmentioning
confidence: 99%
“…Vaccines adjuvanted with Montanide oils have been reported to retain potency for a longer period than conventional aqueous formulations and elicit early, heightened and protective antibody titres and long lasting immunity (Bayry et al., 1999). When administered intramuscularly, no evidence of toxicity, prolonged pyrexia or local reactions at the site of inoculations is reported (Barnett et al., 1996).…”
Section: Discussionmentioning
confidence: 99%
“…Noteworthy, antigen and ISCOM alone or CpG ODN alone were not efficient to induce anti-tumoral immune response and protection in mice. Another example to improve ISCOMS includes tubular immunomodulatory complexes [ 31 , 32 ] or the association with another adjuvant such as Montanide [ 33 ]. For example, when used in combination with a recombinant protein of food and mouth disease virus (FMD) in guinea pigs, higher immune responses were found when ISCOMs and Montanide ISA 206 were used in combination.…”
Section: Immune Stimulating Complexes (Iscoms)mentioning
confidence: 99%
“…An example of a Montanide-based adjuvant is the Incomplete Seppic Adjuvant (ISA™, SEPPIC Inc. Fairfield, NJ, USA), which acts as oil-emulsion adjuvant, and which has been tested in combination with a number of experimental vaccines including a malaria vaccine [ 42 , 43 ]. Also, Montanides and ISCOMs were tested with a recombinant protein vaccine for FMD virus using guinea pigs [ 33 ]. Interestingly, this combination showed the greatest promise in inducing early and long-term protection.…”
Section: Montanidementioning
confidence: 99%
“…Full-length and truncated forms of recombinant DNAderived VP1 (rVP1) of FMDV have been generated previously by several investigators (30). To solve the problem of poor water solubility, however, rVP1 has been routinely used together with denaturing agents such as urea (31).…”
mentioning
confidence: 99%